Natco Pharma Limited has informed the Exchange regarding a press release dated February 13, 2026, titled "Press Release regarding the receipt of Establishment Inspection Report (EIR) for the API Unit located in Chennai from U.S. Food and Drug Administration (FDA)".
NATCOPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved in line with Nifty Smallcap 250 and 0.8 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Natco Pharma's Active Pharmaceutical Ingredient (API) facility in Manali, Chennai has received the Establishment Inspection Report (EIR) from the US FDA. The US FDA had inspected this unit from November 17-21, 2025 and issued 7 observations in the Form-483. The final classification of the inspection is 'Voluntary Action Indicated' (VAI), which is the most favorable outcome and means the FDA does not require any further corrective action from the company. VAI classification confirms that the facility remains in good regulatory standing and can continue to manufacture and supply APIs to the US market without restrictions.
Positive for the stock - clears regulatory uncertainty from the earlier Form-483 observations and removes any overhang on US API exports. With 9 manufacturing sites serving 50+ countries including the US, this outcome preserves revenue continuity from the Chennai API unit and is likely to be viewed favorably by investors.